Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit/Hyperactivity Disorder Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Preventing Behavior Problems in Children With ADHD

NCT00057668
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Multi-Setting Early Intervention, Community Intervention
Behavioral
Lead sponsor
Lehigh University
Other
Eligibility
3 Years to 5 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01654250
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NWP09, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Little Rock, Arkansas • Huntington Beach, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 9:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)

NCT01123668
View directory record Official record
Conditions
Smoking, ADHD
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

NCT03605849
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 9:34 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)

NCT05357495
View directory record Official record
Conditions
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
Interventions
Affective Posner fMRI frustration induction task
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 22, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Terminated Phase 2 Interventional Results available

Impact of Combined Medication and Behavioral Treatment for ASD & ADHD

NCT03242772
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
36 Months to 131 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotine, Non-Smokers With and Without ADHD, and Genetics Study

NCT01819259
View directory record Official record
Conditions
Non-smoker, ADHD
Interventions
Nicotine nasal spray, Placebo
Drug
Lead sponsor
Scott Kollins, PhD
Other
Eligibility
18 Years to 25 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD

NCT02732756
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Healthy Sleep Duration, Shortened Sleep Duration
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

NCT03265119
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

NCT00181948
View directory record Official record
Conditions
ADHD
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional

Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

NCT00029614
View directory record Official record
Conditions
Substance Use Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 22, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional

Fidgeting and Attentional and Emotional Regulation in ADHD

NCT04526600
View directory record Official record
Conditions
ADHD
Interventions
Fidget ball
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 30 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Behavioral Health Treatment for Children in Primary Care

NCT04082234
View directory record Official record
Conditions
ADHD
Interventions
Partnering to Achieve School Success (PASS), Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 11 Years
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT00531752
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PF-03654746, Placebo capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 22, 2026, 9:34 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

How Virtual Reality Can Help Neurodivergent Children Improve Their Attention

NCT07341204
View directory record Official record
Conditions
Autism, Autism Disorder, ADHD - Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder
Interventions
Virtual Reality
Behavioral
Lead sponsor
New York Institute of Technology
Other
Eligibility
9 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Study of the Collaborative Life Skills Program

NCT01686724
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Collaborative Life Skills Intervention (CLS), Business As Usual
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 11 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-9855 Mass Balance Study

NCT01924143
View directory record Official record
Conditions
ADHD, Fibromyalgia
Interventions
TD-9855
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

NCT00191035
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 16 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Rolling Hills Estates, California • Spring Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2006 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01458340
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Bradenton, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01462032
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Training Executive, Attention and Motor Skills (TEAMS), Parent support and education
Behavioral
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
48 Months to 71 Months
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 22, 2026, 9:34 PM EDT
Terminated Not applicable Interventional Results available

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658
View directory record Official record
Conditions
ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute, L1, Lymphoblastic Leukemia, Acute, L2, Lymphoblastic Lymphoma, Lymphocytic Leukemia, Acute, Lymphocytic Leukemia, L1, Lymphocytic Leukemia, L2, Brain Tumors, Cancer of the Brain, Cancer of Brain, Malignant Primary Brain Tumors, Brain Neoplasms, Malignant
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 22, 2026, 9:34 PM EDT